Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- H00000545-M03 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#H00000545-M03, RRID:AB_1144866
- Product name
- Mouse Monoclonal ATR Antibody
- Antibody type
- Monoclonal
- Description
- IgG purified. ATR - ataxia telangiectasia and Rad3 related (1E9)
- Reactivity
- Human, Rat, Hamster
- Host
- Mouse
- Isotype
- IgG
- Vial size
- 0.1 mg
- Storage
- Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Submitted references Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
Savva C, De Souza K, Ali R, Rakha EA, Green AR, Madhusudan S
Breast cancer research and treatment 2019 May;175(1):105-115
Breast cancer research and treatment 2019 May;175(1):105-115
Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
Al-Subhi N, Ali R, Abdel-Fatah T, Moseley PM, Chan SYT, Green AR, Ellis IO, Rakha EA, Madhusudan S
Breast cancer research and treatment 2018 Jun;169(2):277-286
Breast cancer research and treatment 2018 Jun;169(2):277-286
Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.
Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, Rakha E, Ball G, Ellis IO, Curtin NJ, Madhusudan S
Molecular oncology 2015 Mar;9(3):569-85
Molecular oncology 2015 Mar;9(3):569-85
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Abdel-Fatah TM, Perry C, Arora A, Thompson N, Doherty R, Moseley PM, Green AR, Chan SY, Ellis IO, Madhusudan S
Antioxidants & redox signaling 2014 Dec 1;21(16):2262-8
Antioxidants & redox signaling 2014 Dec 1;21(16):2262-8
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
Sultana R, Abdel-Fatah T, Perry C, Moseley P, Albarakti N, Mohan V, Seedhouse C, Chan S, Madhusudan S
PloS one 2013;8(2):e57098
PloS one 2013;8(2):e57098
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: ATR Antibody (1E9) [H00000545-M03] - Analysis of monoclonal antibody to ATR on formalin-fixed paraffin-embedded human placenta. Antibody concentration 3 ug/ml